Astellas Sees Further FDA Action On Prograf MR In Early 2008
This article was originally published in PharmAsia News
Executive Summary
Astellas responded in July to an "approvable" letter received in January for use of the immunosuppressant Prograf MR (tacrolimus) in liver transplantation, the Japanese pharma revealed during its first quarter 2007 earnings call August 1